Heart risks with DPP-4 inhibitors unfounded?

CONCERN over DPP-4 inhibitors being linked to heart failure has been eased by the results of two new trials, experts say.

An Italian case-control study of 282,000 people on diabetes medication found no increased risk of hospitalisation for heart failure, and a 6% lower risk of all-cause mortality, associated with a range of DPP-4 inhibitors.

And the TECOS randomised controlled trial (RCT) of 15,000 patients with cardiovascular disease found that adding sitagliptin to usual care was not linked to hospitalisation for heart failure or major CVD